Table S1: Clinical trials of anti-tumor therapy harnessing macrophage mediated-phagocytosis.

Drug	Phase (status)	Tumor type	Administr-ation route	Strategy	Combination partners	mOS (m)	mPFS (m)	ORR (%)	TRAEs	NCT identifier	Ref.
CD47/SIRPα blockade											
TTI-621	I (terminated)	Relapsed or refractory hematologic malignancies	i.v.	Mono/ combined	Rituximab, nivolumab	NA	NA	13	Infusion-related reactions, thrombocytopenia, chills, fatigue	NCT02663518	[106]
TTI-621	I (terminated)	Mycosis fungoides, Sézary syndrome	i.v.	Mono/ combined	Pembrolizumab, pegylated interferon alpha-2a	NA	NA	NA	Chills, injection site pain, fatigue	NCT02890368	[107]
Evorpacept	I (ongoing)	Solid tumors, lymphoma	i.v.	Mono/ combined	Pembrolizumab, trastuzumab	5.2	1.8	NA	Neutropenia, thrombocytopenia, pancreatitis, death	NCT03013218	[108]
CC-90002	I (terminated)	Myeloid leukemia, myelodysplastic syndromes	i.v.	Mono	-	NA	NA	NA	Diarrhea, thrombocytopenia, febrile neutropenia, aspartate aminotransferase increase	NCT02641002	[95]
Hu5F9-G4	I (completed)	Solid Tumors	i.v.	Mono	-	NA	NA	NA	Transient anemia, hemagglutination on peripheral blood smear, fatigue,	NCT02216409	[92]

Hu5F9-G4	I/II (ongoing)	B-cell non-Hodgkin's lymphoma	i.v.	Combined	Rituximab	NA	NA	NA	headaches, fever, chills Chills, headache, anemia, infusion-related reactions	NCT02953509	[93]
ADCP-potentiating agent											
Daratumumab	I (completed)	Relapsed or refractory MM	i.v.	Mono	-	NA	6.7	NA	Anemia, leukopenia, neutropenia, lymphopenia, upper respiratory tract infection, thrombocytopenia, hypokalemia	NCT02852837	[202]
Daratumumab	III (ongoing)	Relapsed or refractory MM	s.c./i.v.	Mono	-	NA	5.6(s.c.) 6.1(i.v.)	41(s.c.) 37(i.v.)	Anemia, neutropenia, thrombocytopenia	NCT03277105	[203]
Daratumumab	I (ongoing)	Relapsed or refractory MM	s.c.	Mono	-	NA	12	52	Lymphopenia, arthralgia, back pain, thrombocytopenia, diarrhea, nasopharyngitis	NCT02519452	[204]
Daratumumab	III (ongoing)	Newly diagnosed MM	i.v.	Combined	lenalidomide, dexamethasone	NR	NR	NA	Neutropenia, anemia, lymphopenia, pneumonia	NCT02252172	[205]
Daratumumab	I (ongoing)	Relapsed or refractory MM	i.v.	Combined	Carfilzomib, dexamethasone	NR	NR	84	Thrombocytopenia, lymphopenia, anemia, neutropenia	NCT01998971	[206]

Daratumumab	III (ongoing)	Newly diagnosed MM	i.v.	Combined	Bortezomib, melphalan, prednisone	NA	36·4	90.90	Upper respiratory tract infections, bronchitis, viral upper respiratory tract infections, cough, diarrhea	NCT02195479	[207]
Daratumumab	III (ongoing)	Previously treated MM	i.v.	Combined	Bortezomib, dexamethasone	49.6	16.7	NA	Thrombocytopenia, anemia, neutropenia, lymphopenia, pneumonia	NCT02136134	[208]
Daratumumab	III (ongoing)	Previously treated MM	i.v.	Combined	Lenalidomide, dexamethasone	67.6	53.3	NA	Neutropenia, anemia, pneumonia, thrombocytopenia, diarrhea	NCT02076009	[209]
Trastuzumab	III (ongoing)	Previously treated HER2-low advanced breast cancer	i.v.	Mono	-	23.4	9.9	NA	Nausea, fatigue, alopecia	NCT03734029	[210]
Trastuzumab	II (ongoing)	HER2-mutant NSCLC	i.v.	Mono	-	17.8	8.2	NA	Neutropenia, adjudicated drug-related interstitial lung disease	NCT03505710	[211]
Trastuzumab	II (completed)	HER2-expressing metastatic colorectal cancer	i.v.	Mono	-	NA	NA	NA	Lymphocytopenia, neutropenia, fatigue, pneumonia	NCT03384940	[212]

Elotuzumab	III (completed)	Refractory MM	i.v.	Mono	-	NA	19.4	79	Lymphocytopenia, neutropenia, fatigue, pneumonia	NCT01239797	[162]
TLR agonists											
AS15	I (unknown)	Metastatic melanoma	i.m.	Combined	MAGE-A3	33	11.6	NA	Pain, redness, swelling, fever, fatigue, chills, nausea	NCT00086866	[177]
Resiquimod	I (completed)	High-risk melanoma	s.c.	Combined	NY-ESO-1 protein	NA	NA	NA	Influenza-like symptoms, injection site reactions	NCT00821652	[179]
Imiquimod	II (completed)	Breast cancer cutaneous metastases	Applied topically	Combined	Albumin bound paclitaxel	NA	NA	72	92% were grades 1 and 2	NCT00821964	[213]
Imiquimod	II (completed)	Carcinoma in situ bladder cancer	intravesical instillation	Mono	-	NA	NA	NA	Micturition urgency, dysuria, fatigue, hematuria	NCT01731652	[214]
Poly-ICLC	I (completed)	Pancreatic cancer	i.m.	Combined	Peptide-pulsed DC vaccines	7.7	NA	NA	Fatigue, fever, myalgia, chills, night sweats, flashes	NCT01410968	[180]
Motolimod	I (terminated)	SCCHN	s.c.	Combined	Cetuximab	NA	NA	NA	Injection site reaction, rash acneiform, flu-like symptoms, fatigue, diarrhea	NCT02124850	[215]
CSF1R inhibitors											

Emactuzumab	I (completed)	dTGCT	i.v.	Mono	-	NA	NA	71	Pruritus, asthenia, oedema	NCT01494688	[216]
Emactuzumab	I (completed)	Locally advanced dTGCT	i.v.	Mono/ combined	Paclitaxel	NA	NA	NA	Facial oedema, asthenia, pruritus, periorbital oedema, lupus erythematosus, erythema, dermohypodermitis	NCT01494688	[217]
Tasigna	II (completed)	Advanced TGCT	p.o.	Mono	-	NA	77	NA	NA	NCT01261429	[218]
LY3022855	I (completed)	Advanced solid tumors	i.v.	Combined	Durvalumab, tremelimumab	NA	1.87	4.2	Anemia, pyrexia, peritonitis bacterial	NCT02718911	[219]
Pexidartinib	I (completed)	Advanced solid tumors	p.o.	Mono	-	NA	NA	13	Anemia, increased aspartate aminotransferase level, decreased lymphocyte count	NCT02734433	[220]
HDAC inhibitors											
Bisthianostat	I (ongoing)	Relapsed or refractory MM	p.o.	Mono	-	NA	NA	NA	Hematological TRAEs	NCT03618602	[221]
OBP-801	I (ongoing)	Advanced solid tumors	i.v.	Mono	-	NA	NA	NR	Abdominal pain, anemia and fatigue	NCT02414516	[222]

AR-42	II (completed)	Neurofibromatosis type 2-associated tumors, advanced solid malignancies	p.o.	Mono	-	NA	3.6	NA	Cytopenias, fatigue, and nausea	NCT01129193	[223]
AR-42	I (completed)	MM, T- and B-cell lymphomas	p.o.	Mono	-	NA	NA	NA	Cytopenias	NCT01129193	[224]
KA2507	I (completed)	Refractory solid tumors	p.o.	Mono	-	NA	1.8	NA	Fatigue, decreased appetite, urinary tract infection	NCT03008018	[225]
Resminostat	II/III (terminated)	Advanced NSCLC	p.o.	Combined	Docetaxel	15.3	4.1	NA	Leukopenia, febrile neutropenia, thrombocytopenia, anorexia	NCT00473889	[226]
Vorinostat	II (terminated)	Recurrent or metastatic transitional cell carcinoma of the urothelium	p.o.	Mono	-	3.2	1.1	NA	Cytopenias, thrombocytopenic bleeding	NCT00363883	[227]
Mocetinostat	II (completed)	Relapsed or refractory lymphoma	p.o.	Mono	-	12.3 (DLBCL) NR (FL)	2.1 (DLBCL) 3.7 (FL)	18.9 (DLBCL) 11.5 (FL)	Fatigue, nausea, diarrhea	NCT00359086	[228]

Ivaltinostat	I/II (ongoing)	Untreated locally advanced or metastatic Pancreatic adenocarcinoma	i.v.	Combined	Gemcitabine, erlotinib	8.6	5.3	25	Decreased platelet count, decreased appetite, rash	NCT02737228	[229]

Abbreviations: mOS, median overall survival; mPFS, median progression-free survival; ORR, overall response rate; TRAE, treatment-related adverse event; i.v., intravenous; NA, no assessment; MM, multiple myeloma; s.c., subcutaneous; NR, not reached; i.m., intramuscular; NSCLC, non-small-cell lung cancer; IFA, incomplete Freund's adjuvant; SCCHN, squamous cell carcinoma of the head and neck ; dt-GCT, diffuse-type tenosynovial giant cell tumor; TGCT, tenosynovial giant cell tumor; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma.